"Romosozumab in Postmenopausal Women with Low Bone Mineral Density"
NEJM
http://www.nejm.org/doi/full/10.1056/NEJMoa1305224
"CONCLUSIONS

In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532.)"